成人发作性偏头痛管理中的药物安全性 第 1 部分：急性治疗。
Drug Safety in Episodic Migraine Management in Adults Part 1: Acute Treatments.
机构信息
University of Florida, 1149 Newell Dr., L3-100, Gainesville, 32611, USA.
Ayer Neurosciences Institute, Hartford Health Care Medical Group, University of Connecticut School of Medicine, Norwich, CT, USA.
出版信息
Curr Pain Headache Rep. 2022 Jul;26(7):481-492. doi: 10.1007/s11916-022-01057-3. Epub 2022 May 10.
PURPOSE OF REVIEW
The aim of this review is to aid in choosing safe options when assessing potential risks of acute migraine treatments based on known mechanisms of action and anticipated safety concerns.
RECENT FINDINGS
Part 1 highlights safety issues associated with commonly used medications to treat acute migraine attacks. Strategies to mitigate cardiovascular and gastrointestinal risks of nonsteroidal anti-inflammatory drugs, evaluation of cardiovascular risks of triptan and ergot alkaloids, and precautions with use of antiemetics and the novel drugs gepants and ditans are discussed to help practitioners in clinical decision-making. When available, we included recommendations from professional societies and data from pharmacovigilance systems. While guidelines on efficacy are available, one must also consider the possible risks and adverse effects of a drug when creating treatment plans.
目的综述
本文旨在根据已知的作用机制和预期的安全性问题，帮助评估急性偏头痛治疗潜在风险时选择安全的方案。
最近的发现
第 1 部分重点讨论了与治疗急性偏头痛发作常用药物相关的安全性问题。讨论了减轻非甾体抗炎药的心血管和胃肠道风险的策略、评估曲坦类和麦角生物碱的心血管风险，以及使用止吐药和新型 gepants 和 ditans 药物的注意事项，以帮助临床医生做出决策。在可行的情况下，我们纳入了专业协会的建议和药物警戒系统的数据。虽然有关于疗效的指南，但在制定治疗计划时，还必须考虑药物的潜在风险和不良反应。
Zotero 插件